Novartis | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Amgen USD 5.97B 781M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Bausch Health Companies USD 1.81B 130M 2024-09
Biogen USD 1.87B 44.1M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Canopy Growth CAD 24.1M 2.26M 2024-12
Corcept Therapeutics USD 178.93M 745K 2024-12
Drreddys Laboratories INR 49.05B 1.28B 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.56B 57M 2024-12
Glaxosmithkline GBP 5.6B 94M 2024-12
Indivior 248M 1000K 2024-09
J&J USD 15.41B 102M 2024-12
Merck USD 11.92B 852M 2024-12
Novartis USD 10.23B 294M 2024-12
Novartis USD 10.24B 313M 2024-12
Pacira USD 147.37M 17.66M 2024-12
Perrigo USD 385.9M 18.5M 2024-12
Pfizer USD 12.11B 718M 2024-12
Prestige Brands USD 161.05M 3.67M 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 10.07B 2.1B 2024-09
Sanofi EUR 5.36B 4.71B 2024-12
Supernus Pharmaceuticals USD 156.96M 1.14M 2024-12
Zoetis USD 1.61B 79M 2024-12



Novartis Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.